首页> 美国卫生研究院文献>Cancer Biology Medicine >Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification
【2h】

Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification

机译:精准医学时代的急性髓细胞白血病:诊断分类和风险分层的最新进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Acute myeloid leukemia (AML) is a genetically heterogeneous myeloid malignancy that occurs more commonly in adults, and has an increasing incidence, most likely due to increasing age. Precise diagnostic classification of AML requires clinical and pathologic information, the latter including morphologic, immunophenotypic, cytogenetic and molecular genetic analysis. Risk stratification in AML requires cytogenetics evaluation as the most important predictor, with genetic mutations providing additional necessary information. AML with normal cytogenetics comprises about 40%-50% of all AML, and has been intensively investigated. The currently used 2008 World Health Organization classification of hematopoietic neoplasms has been proposed to be updated in 2016, also to include an update on the classification of AML, due to the continuously increasing application of genomic techniques that have led to major advances in our knowledge of the pathogenesis of AML. The purpose of this review is to describe some of these recent major advances in the diagnostic classification and risk stratification of AML.
机译:急性髓细胞性白血病(AML)是遗传异质性髓样恶性肿瘤,在成年人中更常见,并且发病率不断上升,很可能是由于年龄增长所致。 AML的精确诊断分类需要临床和病理学信息,后者包括形态学,免疫表型,细胞遗传学和分子遗传学分析。 AML的风险分层要求将细胞遗传学评估作为最重要的预测指标,而基因突变可提供其他必要信息。具有正常细胞遗传学的AML约占所有AML的40%-50%,并且已经进行了深入研究。提议在2016年更新目前使用的2008年世界卫生组织的造血肿瘤分类,其中还包括AML分类的更新,这是由于基因组技术的应用不断增加,导致我们对AML的发病机制。这篇综述的目的是描述AML的诊断分类和风险分层中的一些最新的重大进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号